Press Release Prescribing Information
Campath® Alemtuzumab - For Intravenous Use Only
SEARCH
 
About Campath
Efficacy
Dosing and Administration
Safety Profile
Clinical Studies
References
Professional Resources
Resources For Patients
CamCareTM Assistance Program
 
   HCP Home  |  Full Prescribing Information (PDF)  |  Contact Us  |  Site Map  
As a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) - See Things in a Whole New Light: Campath First Line - Campath® Alemtuzumab For Intravenous Use Only
Print | Text Size:

 

Contact Us

Services and Support for Healthcare Professionals

For your convenience and assistance, Bayer HealthCare Pharmaceuticals offers a comprehensive range of helpful services that support the use and administration of Campath® therapy.

Bayer HealthCare Pharmaceuticals Medical Information Services

Bayer HealthCare Pharmaceuticals Medical Information Services is a valuable support resource that can help answer medical questions and provide more information about Bayer HealthCare Pharmaceuticals marketed products, including Campath® (alemtuzumab).

1-888-84-BAYER (1-888-842-2937)
8:00am - 5:00pm PT (11:00am - 8:00 pm ET)
Monday through Friday

CamCare™

CamCare is a support program consisting of registered nurses and trained insurance consultants who are available to help you support your patients and their caregivers during Campath® (Alemtuzumab) treatment. For this information visit the Camcare section of this site or call the CamCare Support Line at 1-800-473-5832

Bayer HealthCare Pharmaceuticals Sales Consultants

To contact your Bayer HealthCare Pharmaceuticals sales consultant, call 1-888-84-BAYER (1-888-842-2937).

Indication and Important Safety Information

Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).

WARNING: CYTOPENIAS, INFUSION REACTIONS, and INFECTIONS

Cytopenias: Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving Campath. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia [see WARNINGS AND PRECAUTIONS (5.1)].

Infusion Reactions: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days [see DOSAGE AND ADMINISTRATION (2) and WARNINGS AND PRECAUTIONS (5.2)].

Infections: Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.3)].

The most commonly reported adverse reactions are infusion reactions fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings and Precautions," and "Adverse Reactions" sections of full Prescribing Information.

Please see Full Prescribing Information (PDF).